AZ Lp(a) Licensing Deal; Novo Reaches Semaglutide Patent Settlement with Viatris; Trinity Completes Pre-Pivotal CGM Trial
Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: AstraZeneca announced a licensing deal with CSPC Pharmaceutical Group for a preclinical oral Lp(a) disruptor (view press release); Novo Nordisk and Viatris have settled a lawsuit over one of Novo’s semaglutide patents (view article); and Trinity Biotech announced the completion of its EU pre-pivotal CGM trial (view press release). Below, FENIX provides highlights and insights for the respective news items.